This Week in Tech

This Week in Tech

# 5 New Tech Ventures Shaking Up the World Right Now


The tech world doesn't slow down β€” and the last few weeks have delivered some genuinely jaw-dropping stories. From AI agents that work while you sleep to satellites that talk to the Bluetooth chip already in your pocket, here are five new ventures worth knowing about.


---


## 1. Manus: The AI Agent That Refused to Be Bought


Manus, built by parent company Butterfly Effect, makes general-purpose AI agents β€” software that doesn't just answer questions but actually *does* multi-step work: research, coding, document prep, automation. In September they launched a major agent upgrade plus a standalone app called Cue for building your own personal AI agents.


The backstory is wilder than the tech. In December 2025, Meta announced a $2 billion-plus acquisition of Manus. Four months later, Chinese regulators ordered the deal unwound over concerns about foreign control of advanced AI. Manus went independent again in August β€” and on October 8, 2026, raised more than **$500 million** co-led by Boyu Capital and IDG Capital, reportedly targeting a ~$4 billion valuation. That's roughly double what Meta was going to pay. The Information reports their annualized revenue run rate hit ~$500 million by June.


**Why it matters:** The AI race is shifting from chatbots to agents that do real work. Manus betting on independence β€” and winning β€” says the market agrees.


---


## 2. Maven Robotics: General-Purpose Robots for the Factory Floor


Out of stealth on September 10, 2026, Santa Clara-based Maven Robotics is building what it calls the world's first general-purpose robotics system for industrial work β€” hardware, software, and AI integrated across the robot, the fleet, and the factory itself.


They launched with a **$100 million Series A** (RoboStrategy, LocalGlobe, Vine Ventures, XTX Ventures) and started with mixed-case palletizing and tote handling β€” an $80 billion market on its own β€” with plans to expand into material handling and assembly workflows they estimate above $1 trillion. The timing is no accident: US manufacturing is staring at 480,000+ unfilled jobs.


**Why it matters:** Industrial robots have historically done one thing well. A genuinely general-purpose factory robot would be as big a leap as the programmable computer was over the calculator.


---


## 3. Hubble Network: Satellites That Talk to Your Bluetooth


Seattle startup Hubble Network is building a satellite constellation with a killer trick: it connects to the standard Bluetooth Low Energy radios *already inside billions of devices*. A firmware update is all it takes β€” no cellular modem, no GPS chip, no dedicated satellite hardware β€” and suddenly any device can transmit location and sensor data from anywhere on Earth.


On September 23, 2026, they raised **$200 million in Series C** at a $1.6 billion valuation (led by Smith Point Capital, $300M total raised) and opened the constellation to general availability the same day. The plan: grow from 6 satellites to 60 by 2030. They've already lined up partnerships with Texas Instruments and smart-label maker Reelables.


**Why it matters:** Global tracking for the cost of a firmware update could rewrite logistics, agriculture, and wildlife conservation β€” anywhere cellular doesn't reach.


---


## 4. Solstice Oncology: A $225M Bet on Smarter Cancer Treatment


Boston biotech Solstice Oncology emerged from stealth in February 2026 developing porustobart, an anti-CTLA-4 antibody licensed from China's Harbour BioMed in a $105 million deal, designed to be combined with Merck's Keytruda.


On September 9 they raised a **$225 million Series A** led by RA Capital β€” the biggest biopharma launch of Q3 2026, according to BioSpace. The FDA has cleared a Phase 2 trial of the porustobart/Keytruda combination in advanced colon cancer, with data expected in late 2027. Early results are promising: Harbour's earlier Phase 2 showed a 30% objective response rate in a hard-to-treat colorectal cancer subtype.


**Why it matters:** Combination immunotherapies are where oncology's biggest wins are coming from. A quarter-billion-dollar launch says investors think this one has a real shot.


---


## 5. Helical Fusion: Japan's Bet on Star Power


Tokyo-based Helical Fusion is developing a helical stellarator reactor β€” a twist on the fusion design most famously pursued by Germany's Wendelstein 7-X β€” aiming for commercially viable fusion power in the 2030s through its Helix Program.


On October 8, 2026, they closed a **Β₯3.23 billion (~$20.6M) Series B second close**, with industrial giant Fuji Electric joining as both investor and Official Partner β€” alongside Fujikura (superconducting materials) and Tokyo Gas. Total funding is now ~Β₯13.15 billion (~$83.8M) including grants and loans. The real signal here isn't the amount β€” it's *who's* paying: Japanese heavy industry is starting to finance an actual fusion supply chain, not just lab research.Β Fusion has been "30 years away" for 50 years. When the companies that build power plants start writing checks, the timeline starts looking real

The Takeaway


AI agents going independent, general-purpose factory robots, Bluetooth-to-space, quarter-billion-dollar cancer bets, and industry-backed fusion β€” all in the last month. The throughline? The most exciting ventures right now aren't apps. They're atoms: robots, satellites, medicine, and energy. The physical world is having its software moment.


*Sources: R

euters, TechCrunch, GlobeNewswire, BioSpace, Business Wire.*